EGFR and non-small cell lung carcinoma: A study comparing AREG expression in 24 EGFR wild type NSCLC patients found AREG expression was significantly higher in NSCLC patients who developed stable disease following gefitinib or erlotinib treatment compared with those who developed disease progression [16].